Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Hoth Therapeutics (NASDAQ: HOTH) has partnered with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer's disease treatment. This collaboration follows promising pre-clinical results that demonstrated HT-ALZ's ability to improve cognitive functions and quality of life in subjects with Alzheimer's.
The treatment showed potential to reduce brain inflammation, leading to improved cognitive outcomes. Pre-clinical research indicated HT-ALZ's capacity to enhance memory tasks related to the hippocampus and sensorimotor gating. The prototype development will support a future Investigational New Drug (IND) Application to initiate clinical trials, marking a significant step in Hoth's innovative approach to Alzheimer's treatment.
Hoth Therapeutics (NASDAQ: HOTH) ha stretto una partnership con LTS Therapy Systems per sviluppare e produrre il prototipo di film orale HT-ALZ per il trattamento dell'Alzheimer. Questa collaborazione segue risultati preclinici promettenti che hanno dimostrato la capacità di HT-ALZ di migliorare le funzioni cognitive e la qualità della vita nei soggetti affetti da Alzheimer.
Il trattamento ha mostrato potenzialità nel ridurre l'infiammazione cerebrale, portando a risultati cognitivi migliorati. La ricerca preclinica ha indicato la capacità di HT-ALZ di migliorare i compiti di memoria legati all'ippocampo e il gating sensomotorio. Lo sviluppo del prototipo supporterà una futura Domanda di Nuovo Farmaco Investigativo (IND) per avviare studi clinici, segnando un passo significativo nell'approccio innovativo di Hoth al trattamento dell'Alzheimer.
Hoth Therapeutics (NASDAQ: HOTH) ha establecido una asociación con LTS Therapy Systems para desarrollar y fabricar el prototipo de película oral HT-ALZ para el tratamiento de la enfermedad de Alzheimer. Esta colaboración sigue resultados preclínicos prometedores que demostraron la capacidad de HT-ALZ para mejorar las funciones cognitivas y la calidad de vida en sujetos con Alzheimer.
El tratamiento mostró potencial para reducir la inflamación cerebral, lo que conduce a mejores resultados cognitivos. La investigación preclínica indicó la capacidad de HT-ALZ para mejorar las tareas de memoria relacionadas con el hipocampo y el gating sensoriomotor. El desarrollo del prototipo apoyará una futura Solicitud de Nuevo Medicamento de Investigación (IND) para iniciar ensayos clínicos, marcando un paso significativo en el enfoque innovador de Hoth para el tratamiento del Alzheimer.
Hoth Therapeutics (NASDAQ: HOTH)는 알츠하이머 병 치료를 위한 HT-ALZ 구강 필름 프로토타입을 개발하고 제조하기 위해 LTS Therapy Systems와 협력했습니다. 이 협력은 HT-ALZ가 알츠하이머 환자의 인지 기능 및 삶의 질을 개선할 수 있다는 유망한 전임상 결과를 바탕으로 진행되었습니다.
이 치료법은 뇌 염증을 줄일 수 있는 가능성을 보였으며, 그 결과 인지 결과가 개선되었습니다. 전임상 연구는 HT-ALZ가 해마와 관련된 기억 과제와 감각 운동 억제를 향상시킬 수 있는 능력이 있음을 나타냈습니다. 프로토타입 개발은 임상 시험을 시작하기 위한 향후 새로운 약물 연구 신청(IND)을 지원할 것이며, Hoth의 알츠하이머 치료에 대한 혁신적인 접근 방식의 중요한 진전을 알립니다.
Hoth Therapeutics (NASDAQ: HOTH) a établi un partenariat avec LTS Therapy Systems pour développer et fabriquer le prototype de film oral HT-ALZ pour le traitement de la maladie d'Alzheimer. Cette collaboration fait suite à des résultats précliniques prometteurs qui ont démontré la capacité de HT-ALZ à améliorer les fonctions cognitives et la qualité de vie des sujets atteints de la maladie d'Alzheimer.
Le traitement a montré un potentiel pour réduire l'inflammation cérébrale, entraînant une amélioration des résultats cognitifs. La recherche préclinique a indiqué la capacité de HT-ALZ à améliorer les tâches de mémoire liées à l'hippocampe et le gating sensorimoteur. Le développement du prototype soutiendra une future Demande de Nouveau Médicament Investigateur (IND) pour initier des essais cliniques, marquant une étape significative dans l'approche innovante de Hoth pour le traitement de la maladie d'Alzheimer.
Hoth Therapeutics (NASDAQ: HOTH) hat eine Partnerschaft mit LTS Therapy Systems geschlossen, um den HT-ALZ orale Filmprototyp zur Behandlung der Alzheimer-Krankheit zu entwickeln und herzustellen. Diese Zusammenarbeit folgt vielversprechenden präklinischen Ergebnissen, die gezeigt haben, dass HT-ALZ in der Lage ist, kognitive Funktionen und die Lebensqualität bei Alzheimer-Patienten zu verbessern.
Die Behandlung zeigte Potenzial, um Gehirnentzündungen zu reduzieren, was zu verbesserten kognitiven Ergebnissen führte. Die präklinische Forschung deutete darauf hin, dass HT-ALZ in der Lage ist, Gedächtnisaufgaben im Zusammenhang mit dem Hippocampus und sensorische Gate-Funktionen zu verbessern. Die Prototypentwicklung wird eine zukünftige Antrag auf neue Untersuchungsmedizin (IND) unterstützen, um klinische Studien einzuleiten, was einen bedeutenden Schritt im innovativen Ansatz von Hoth zur Alzheimer-Behandlung darstellt.
- Partnership with LTS Therapy Systems to develop and manufacture HT-ALZ oral film prototype
- Promising pre-clinical results showing cognitive benefits and improved quality of life for Alzheimer's subjects
- Potential reduction in brain inflammation, leading to improved cognitive outcomes
- Demonstrated improvement in memory tasks and sensorimotor gating in pre-clinical research
- Progress towards Investigational New Drug (IND) Application for clinical trials
- None.
The partnership between Hoth Therapeutics and LTS Therapy Systems for the development of HT-ALZ is a notable step forward in Alzheimer's research. This collaboration leverages LTS's established expertise in film-based drug delivery, which could enhance the bioavailability and patient compliance of HT-ALZ. The pre-clinical results showing cognitive improvements and reduced brain inflammation are promising. However, it is important to understand that these benefits observed in pre-clinical models do not always translate directly to human patients. The upcoming stages, particularly clinical trials, will be critical in determining the actual efficacy and safety of HT-ALZ in treating Alzheimer's disease.
From a financial perspective, this partnership represents a strategic alignment that could potentially de-risk the development process for Hoth Therapeutics. Collaborating with LTS Therapy Systems allows Hoth to leverage specialized manufacturing capabilities, which can streamline the pathway to an IND application. If the subsequent clinical trials confirm the pre-clinical benefits, Hoth could see a substantial increase in its market valuation. However, investors should remain cautious as the development of Alzheimer's treatments is notoriously challenging, with a high failure rate in clinical stages. Monitoring cash flow, funding sources and partnership terms will be key to assessing Hoth's financial health moving forward.
The Alzheimer's treatment market is highly competitive but also offers substantial opportunities due to the unmet need for effective therapies. The positive pre-clinical results for HT-ALZ could position Hoth Therapeutics well within this landscape. The use of oral film as a delivery method could differentiate HT-ALZ from other treatments, especially if it proves to increase patient compliance. However, market acceptance will heavily depend on the clinical trial outcomes and subsequent regulatory approvals. Thus, while the partnership with LTS is a significant step, the long-term market potential will be clearer only after seeing the results of clinical trials and regulatory feedback.
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.
HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease
The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.
"Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ," stated Robb Knie, Chief Executive Officer. "We are leveraging LTS's expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer's therapeutic ."
The HT-ALZ prototype development and manufacturing work by LTS will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials. For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-partners-with-lts-therapy-systems-to-accelerate-novel-alzheimers-treatment-302204772.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the purpose of Hoth Therapeutics' partnership with LTS Therapy Systems?
What were the key findings from HT-ALZ's pre-clinical trials?
How does Hoth Therapeutics (HOTH) plan to advance HT-ALZ towards clinical trials?
What is the potential impact of HT-ALZ on Alzheimer's patients?
